In prostate cancer, elevated serum levels of YKL40 had been reported in primary prostate cancer patients when compared with benign prostate hyperplasia patients, considering that YKL40 may affect the aggressiveness and progression of prostate cancer (Kucur et al., 2008). Here, CHI3L1 is linked to benign prostatic hyperplasia.